Effectiveness of dapagliflozin in nonalcoholic fatty liver disease in type 2 diabetes patients compared to sitagliptin and pioglitazone

被引：0
|
作者：
Koutsovasilis, A.
Sotiropoulos, A.
Bletsa, E.
Antoniou, A.
Tamvakos, C.
Ntionias, D.
Bousboulas, S.
Peppas, T.
机构：
[1] Gen Hosp Nikaia Piraeus, Dept Internal Med 3, Athens, Greece
[2] Gen Hosp Nikaia Piraeus, Ctr Diabet, Athens, Greece
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
12
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [1] The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone
    Koutsovasilis, Anastasios
    Sotiropoulos, Alexios
    Pappa, Maria
    Papadaki, Despina
    Kordinas, Vasilis
    Tamvakos, Charalampos
    Bourikou, Maria
    Bousboulas, Stavros
    Peppas, Theodoros
    DIABETES, 2018, 67
  • [2] The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
    Ohki, Takamasa
    Isogawa, Akihiro
    Iwamoto, Masahiko
    Ohsugi, Mitsuru
    Yoshida, Haruhiko
    Toda, Nobuo
    Tagawa, Kazumi
    Omata, Masao
    Koike, Kazuhiko
    SCIENTIFIC WORLD JOURNAL, 2012,
  • [3] Effectiveness of lixisenatide in nonalcoholic fatty liver disease in patients with type 2 diabetes after an acute coronary syndrome compared to sitagliptin and pioglitazone
    Koutsovasilis, A.
    Sotiropoulos, A.
    Pappa, M.
    Apostolou, O.
    Binikos, I.
    Kordinas, V.
    Papadaki, D.
    Tamvakos, I.
    Bousboulas, S.
    DIABETOLOGIA, 2016, 59 : S369 - S370
  • [4] The effect of the combination of dapagliflozin and liraglutide in non alcoholic fatty liver disease in patients with type 2 diabetes compared to sitagliptin and pioglitazone
    Koutsovasilis, A.
    Sotiropoulos, A.
    Papadaki, D.
    Pappa, M.
    Kordinas, V.
    Bousboulas, S.
    Peppas, T.
    DIABETOLOGIA, 2018, 61 : S590 - S590
  • [5] The Effectiveness of Liraglutide in Non-alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
    Ohki, Takamasa
    Akihiro, Isogawa
    Ooga, Takafumi
    Sato, Koki
    Fujiwara, Hiroaki
    Seki, Michiharu
    Toda, Nobuo
    Tagawa, Kazumi
    HEPATOLOGY, 2012, 56 : 906A - 906A
  • [6] Dapagliflozin Therapy in Type 2 Diabetes Patients with nonalcoholic Fatty Liver Disease
    Kahl, S.
    DIABETOLOGE, 2018, 14 (07): : 506 - 508
  • [7] The Short- and Long-Term Influence of Lixisenatide in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone
    Koutsovasilis, Anastasios
    Sotiropoulos, Alexios
    Bletsa, Evdoxia
    Kordinas, Vasilis
    Elvanidi, Sofia
    Panagiotou, Dimitrios
    Skliros, Efstathios
    Bousboulas, Stavros
    Peppas, Theodoros
    DIABETES, 2017, 66 : A675 - A675
  • [8] Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease
    Wang, Chao-Hung
    Leung, Ching-Hsiang
    Liu, Sung-Chen
    Chung, Cheng-Ho
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2006, 105 (09) : 743 - 752
  • [9] Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Gramlich, Terry
    Matteoni, Christi A.
    Boparai, Navdeep
    Mccullough, Arthur J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (03) : 262 - 265
  • [10] Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis
    Duan, Hua
    Chen, Fangyuan
    MEDICINE, 2025, 104 (01)
12345